HistoSonics Announces Financing with Participation from Yosemite

The funding comes as the company continues to gain strong momentum, with growing global adoption of its non-invasive histotripsy treatment for liver tumors. HistoSonics is also expanding the use of its technology to treat additional types of solid tumors.

Over the past year, HistoSonics has made strong progress in treating liver tumors, including metastatic cases, with increasing use by physicians at leading hospitals and academic medical centers.

The company has also submitted a De Novo request to the U.S. FDA for clearance to treat kidney tumors, which would significantly expand the use of its technology. In addition, HistoSonics is seeing encouraging early results in treating primary pancreatic tumors, a condition with high unmet medical need, and is moving toward a future FDA submission as clinical progress continues.

Read More:DropGenie Closes Seed+ Funding Round Led by Skeleton Key

Histotripsy is a non-invasive treatment that uses focused ultrasound energy and sound waves to break down targeted tissue without surgery or radiation, and it may result in fewer side effects compared to traditional treatments. The Edison Histotripsy System has received U.S. FDA De Novo clearance for treating liver tumors and is now being used more widely in the United States and internationally. Its use for conditions outside the liver is still limited to clinical research.

"Building a generational company requires partners who bring more than capital,” commented Mike Blue, Chairman & CEO, HistoSonics. This financing continues to add strategic investors who understand our mission, appreciate the magnitude of the opportunity ahead and share our commitment to delivering lasting value for patients, physicians and shareholders."

“Yosemite’s mission is to help accelerate technologies that have the potential to change outcomes for patients meaningfully,” said Reed Jobs. “And for me it’s a personal mission. HistoSonics is pioneering an entirely new approach to addressing some of the world’s deadliest cancers and diseases, and we are excited to support the company as it expands the reach of histotripsy throughout the entire body.”

About HistoSonics

Founded in 2009, HistoSonics is a privately held medical device company developing a non-invasive treatment platform based on histotripsy, a technology that uses focused ultrasound energy to break down and liquefy unwanted tissue and tumors without surgery. The company is currently focused on commercializing its Edison System in the United States and selected global markets for liver tumor treatment, while also working to expand its use to other organs such as the kidney, pancreas, prostate, and more.

Read More:Bionyra Pharma Raises $165M in Series A Funding